Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics

We recently discovered mutation signatures reminiscent of BRCA deficiency in the vast majority of a set of primary osteosarcomas (OS). In the current study, we therefore investigated the sensitivity of a panel of OS cell lines to the poly(ADP)-ribose polymerase (PARP) inhibitor talazoparib alone and...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncotarget
Auteurs principaux: Engert, Florian, Kovac, Michal, Baumhoer, Daniel, Nathrath, Michaela, Fulda, Simone
Format: Artigo
Langue:Inglês
Publié: Impact Journals LLC 2016
Sujets:
Research Paper
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5564725/
https://ncbi.nlm.nih.gov/pubmed/27447864
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.10720
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires